We are live on
!
Find out more
FFVM
Founders Fund V Management Portfolio holdings
AUM
$2.16M
1-Year Est. Return
77.37%
This Fund
S&P 500
This Quarter
Est. Return
+5.31%
1 Year Est. Return
+77.37%
3 Year Est. Return
+859.57%
5 Year Est. Return
-74.2%
10 Year Est. Return
–
AUM
$947K
AUM Growth
+$144K
(+18%)
Cap. Flow
+$45.6K
Cap. Flow
% of AUM
4.82%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYTH
Cyclo Therapeutics, Inc. Common Stock
CYTH
|
+$613K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
|
+$567K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.78% |
| 2 | Technology | 9.22% |
Similar funds
NA
FFVM
IVSFI
MI
AICPI
FFVM
SNN
AC
Founders Fund V Management's Q4 2023 Portfolio in Review
As of Q4 2023, Founders Fund V Management held 4 positions worth $947K, up 18% from $803K the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Founders Fund V Management deployed $45.6K of net new capital in Q4 2023, opening 1 new position. Its largest new stake was Cyclo Therapeutics, Inc. Common Stock: 480,708 shares worth $764K.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier, followed by Technology.
On the sell side, the most notable exit was Applied Molecular Transport Inc. Common Stock, an estimated $567K sold.
- Founders Fund V Management's largest Q4 2023 buy was Cyclo Therapeutics, Inc. Common Stock: 480,708 shares worth $764K.
- Founders Fund V Management fully exited Applied Molecular Transport Inc. Common Stock in Q4 2023, selling an estimated $567K.
- Founders Fund V Management's ten largest holdings make up 100% of its $947K portfolio in Q4 2023.
- Founders Fund V Management opened 1 new position and closed 1 in Q4 2023.
- Founders Fund V Management's portfolio value rose 18% quarter-over-quarter to $947K.
Based on Founders Fund V Management's 13F filing for Q4 2023, filed 14 Feb 2024.